These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20963456)

  • 21. XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products.
    Li H; Zheng X; Wang H; Zhang Y; Xin H; Chen X
    Eur J Pharmacol; 2010 Feb; 627(1-3):340-7. PubMed ID: 19895808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of advanced glycation end product modification on proximal tubule epithelial cell processing of albumin.
    Ozdemir AM; Hopfer U; Rosca MV; Fan XJ; Monnier VM; Weiss MF
    Am J Nephrol; 2008; 28(1):14-24. PubMed ID: 17890854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.
    Cooper ME
    Am J Hypertens; 2004 Dec; 17(12 Pt 2):31S-38S. PubMed ID: 15607433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
    Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats.
    Soulis T; Cooper ME; Sastra S; Thallas V; Panagiotopoulos S; Bjerrum OJ; Jerums G
    Diabetologia; 1997 Oct; 40(10):1141-51. PubMed ID: 9349594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
    Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced glycation in diabetic renal and vascular disease.
    Vlassara H
    Kidney Int Suppl; 1995 Sep; 51():S43-4. PubMed ID: 7474689
    [No Abstract]   [Full Text] [Related]  

  • 28. [The pathogenetic role of advanced glycation end products in diabetic nephropathy].
    Zhou J; Zhang Y; Lu HY
    Sheng Li Ke Xue Jin Zhan; 2009 Oct; 40(4):372-4. PubMed ID: 21417044
    [No Abstract]   [Full Text] [Related]  

  • 29. Ellagic acid inhibits non-enzymatic glycation and prevents proteinuria in diabetic rats.
    Raghu G; Jakhotia S; Yadagiri Reddy P; Kumar PA; Bhanuprakash Reddy G
    Food Funct; 2016 Mar; 7(3):1574-83. PubMed ID: 26902315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced glycation end products.
    Thomas MC
    Contrib Nephrol; 2011; 170():66-74. PubMed ID: 21659759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advanced glycation end products (AGEs) and renal failure].
    Kurowski R; Manitius J
    Przegl Lek; 2006; 63(4):203-8. PubMed ID: 17080743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetic nephropathy and advanced glycation end products.
    Menè P; Festuccia F; Polci R; Pugliese F; Cinotti GA
    Contrib Nephrol; 2001; (131):22-32. PubMed ID: 11125560
    [No Abstract]   [Full Text] [Related]  

  • 33. N2-carboxyethyl-2'-deoxyguanosine, a DNA glycation marker, in kidneys and aortas of diabetic and uremic patients.
    Li H; Nakamura S; Miyazaki S; Morita T; Suzuki M; Pischetsrieder M; Niwa T
    Kidney Int; 2006 Jan; 69(2):388-92. PubMed ID: 16408131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced glycosylation end products in diabetic renal and vascular disease.
    Bucala R; Vlassara H
    Am J Kidney Dis; 1995 Dec; 26(6):875-88. PubMed ID: 7503061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy.
    Nishino T; Horii Y; Shiiki H; Yamamoto H; Makita Z; Bucala R; Dohi K
    Hum Pathol; 1995 Mar; 26(3):308-13. PubMed ID: 7890283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycation free adduct accumulation in renal disease: the new AGE.
    Thornalley PJ
    Pediatr Nephrol; 2005 Nov; 20(11):1515-22. PubMed ID: 16133053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease.
    Dou L; Jourde-Chiche N
    Toxins (Basel); 2019 Oct; 11(10):. PubMed ID: 31590361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Toxicity of glucose: is AGE the answer?'.
    Makita Z
    Nephrol Dial Transplant; 1995; 10 Suppl 7():33-7. PubMed ID: 8570076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced glycosylation endproducts in diabetic renal disease: clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition.
    Bucala R; Vlassara H
    Blood Purif; 1995; 13(3-4):160-70. PubMed ID: 7619388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. D-ribose in glycation and protein aggregation.
    Wei Y; Han CS; Zhou J; Liu Y; Chen L; He RQ
    Biochim Biophys Acta; 2012 Apr; 1820(4):488-94. PubMed ID: 22274132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.